Acute myelomonocytic leukemia (AMMoL) is a form of acute myeloid leukemia that involves a proliferation of CFU-GM myeloblasts and monoblasts.
It is classified under "M4" in the French-American-British classification (FAB).
It is classified under "AML, not otherwise classified" in the WHO classification.
Translocations have been observed.
Progression from myelodysplastic syndrome has been reported.
Acute myeloblastic leukemia (AML) is a group of malignant bone marrow neoplasms of myeloid precursors of white blood cells. Acute myelomonocytic leukemia (AML-M4) is a common type of pediatric AML. However, the condition is rare and represents approximately 3 % of all leukemias during childhood and has an incidence of 1.1 – 1.7 per million per year. The symptoms may be aspecific: asthenia, pallor, fever, dizziness and respiratory symptoms. More specific symptoms are bruises and/or (excessive)bleeding, coagulation disorders (DIC), neurological disorders and gingival hyperplasia. Diagnosticmethods include blood analysis, bone marrow aspirate for cytochemical, immunological and cytogeneticalanalysis, and cerebrospinal fluid (CSF) investigations. A characteristic chromosomal abnormalityobserved in AML-M4 is inv(16). Treatment includes intensive multidrug chemotherapy and in selected cases allogeneic bone marrow transplantation. Nevertheless, outcome of AML remains poor with an overall survival of 35-60%. Children with AML-M4 carrying the inv(16) abnormality have a better prognosis (61% 5-year overall survival). New therapeutics are required to increase the probability of cure in this serious disorder.
Famous quotes containing the word acute:
“Biography should be written by an acute enemy.”
—A.J. (Arthur James)